Dr. Lo and colleagues hope that by using adipsin or DUSP26 therapies, patients with type 2 diabetes will be spared from developing beta cell failure and thus spared from insulin injections.
In a collaborative study, Dr. John R. Lee and colleagues revealed a first-of-its-kind discovery showing that the abundance of uropathogens in the gut is associated with future development of UTI.
Funded by a $22 million grant from the National Institutes of Health and Three Lakes Partners, the PRECISIONS study aims to transform diagnosis and treatment for idiopathic pulmonary fibrosis.
Results of a recent study that used a new drug combination (glecaprevir/pibrentasivr) for chronic HCV and compensated cirrhosis of the liver, showed high virological cure rates.
The grant seeks to understand the opportunities and challenges posed by cognitive restoration for people with severe to moderate traumatic brain injury in the context of the Americans with Disabilities Act.
Dr. Melnick and his team have developed an SIRT3-blocking compound that rapidly kills diffuse large B cell lymphoma cells in the culture dish and in mice.
Dr. Czaja utilizes technology to facilitate the performance of older workers, to assist dementia caregivers, to enable older adults to use e-health apps and the Internet, and to support memory and social connectivity.
The paper illuminates a technique that has enabled a low-cost urine test that can identify thousands of bacteria and viruses in humans. Importantly, infections causing tissue damage can be readily discerned.
The CSDA will provide Dr. Dupnik with $495,000 over three years in support of her research studies in the area of infectious diseases.
This award is presented annually to members of the Weill Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research.